Connect with us

Uncategorized

US consumers are now noticing inflation

Published

on

(FinancialPress) — The University of Michigan has released a report on US consumer sentiment in August. Consumers perceive the current economic climate as “much less favorable“ for buying conditions, “mainly due to less favorable perceptions of market prices.”

In layman‘s terms, they feel things are pricier now, and have started to reduce their consumption.

UoM‘s headline consumer sentiment index dropped to 95.3 in early August –  a 2.6 slide from its end of July mark of 97.9. The new number also holds the record for being the lowest the index has gone in 11 months. Consumers‘ perception of current economic condition also went down to 107.8 from its previous mark of 111.4 in late July – a new low in just about two years.

Large household acquisitions dropped even more, reaching their lower point in 4 years.

Richard Curtin, who served as chief economist for the investigation, said that “buying conditions for large household durables sank to the lowest level in nearly four years.”

“When asked to explain their views, consumers voiced the least favorable views on pricing for household durables in nearly ten years, since October 2008. Vehicle buying conditions were viewed less favorably in August than anytime in the last four years, with vehicle prices being judged less favorably than anytime since the close of 1984. Home buying conditions were viewed less favorably in early August than anytime in the past ten years, with home prices judged less favorably than anytime since 2006.”

July saw “core“ inflation rise 2.4% year-on-year – the biggest rise in almost ten years. Headline inflation, in turn, rose 2.9% year-on-year – a six-year-high itself.

Curtin noted that the change in perception is “extraordinary“, as no major shifts in inflation outlook happened in July.

Ruben is a South American writer who focuses on the state of the cryptocurrency, cannabis and tech industries worldwide.

Uncategorized

Investors See Major Growth Potential In Plant Medicine

Published

on

This Could Be the Secret to Treating Chron’s Diseases & IBD

Innovations in cutting edge, plant based pharmaceuticals are changing the way investors think about next generation medicines, and way we treat intractable neurological, gastrointestinal, psychiatric, musculoskeletal, and other sorts of diseases.

 

A number of biopharmaceutical companies are aiming to generate solutions to these conditions. Among them include drug developers like Cara Therapeutics to treat pain and pruritus, Protagonist Therapeutics for IBD and Crohn’s, and Zogenix for epilepsy and seizures.

However, unlike several other companies in the space, publicly traded Vitality Biopharma (VBIO:OTCQB) is already ahead of the curve in its development of highly valuable IP.

 

Vitality Bio is a stock positioned for growth in the imminent future. Pioneering new technologies and compounds in the biopharmaceutical space, Vitality Bio is among the world’s only drug developers to generate a new class of groundbreaking pharmaceuticals using glycosylation technology. Distinct from its peers, Vitality Bio has the advantage of being at the forefront of developing pharmaceutical cannabis medicine, patenting technological enhancement of plant compounds otherwise found in nature. It’s targeting diseases like Crohn’s and IBD, filling a much needed role in that particular market of the medical industry.

In fact, technology like Vitality BioPharma’s could help millions: According to the Crohn’s & Colitis Foundation of America, approximately 1.6 million Americans, including 80,000 children, suffer from inflammatory bowel disease. In a recent report entitled “Crohn’s Disease Market: Global Industry Analysis and Forecast, 2016-2024,” researchers found that the anti-inflammatory drug segment of the pharmaceutical market is anticipated to be the most lucrative segment through 2024.

A market this size is worth investing in to find solutions.

To invest in such a company is to take advantage of the plant molecular medicine’s profit potential in treating diseases like Crohn’s and IBD, minus the psychoactive effects. It’s already well known that the plants molecules are effective medicine, and similar  pharmaceutical companies are having a hard time reinventing the wheel. However, through glycosylation, they can deliver this medicine in as streamlined and effective a way as possible.

What’s more, while no pharmaceutical company can patent the molecules of the plant because they occur in nature, but by a modifying them adding glucose, a company like Vitality Bio can and has applied for a patent.” The company has filed intellectual property applications and is now seeking worldwide patent protection through 2035 for prodrugs based on these powerful molecules and other compounds, as well as for proprietary prodrug biosynthesis platform utilizing enzymatic glycosylation.

 

Listen to the EXCLUSIVE Interview with Robert Brooke, CEO of VBIO:OTCQB

 

With regard to Vitality Bio, the company’s class of prodrugs are both FDA and DEA approved, and filed as intellectual property. They unlock the potential of plant based molecules to deliver therapy in a safe, effective, targeted fashion — without any psychoactive effects. The company currently focuses on neurological and gastrointestinal relief.

Get the Investor Report on This Company


 

Dr. David Ziring, pediatric gastroenterologist at Cedars-Sinai Medical Center in Los Angeles has claimed many families who seek alternatives to standard pharmaceuticals because of toxicity issues and inadequate response to current market drugs have found the molecules in the plant an effective treatment for IBD.

 

Let’s look at the market comparables

Featured company that appears undervalued compared to it’s peers:

Vitality Biopharma Inc. (OTCQB:VBIO)

Market Cap: $45M

Vitality is developing proprietary plant-based pharmaceuticals that are compliant with FDA and DEA regulations. Oral pharmaceuticals are a convenient and desirable option for patients and physicians, and they could help realize the full therapeutic potential of cannabinoid medicines.

Using a proprietary glycosylation platform, Vitality Biopharma (VBIO:OTCQB) has been able to produce more than 20 novel combinations which together represent a new class of pharmaceuticals.


Other Large-cap players in the space include:

Cara Therapeutics Inc. (NASDAQ:CARA)

Market Cap: $420M

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.

 

Protagonist Therapeutics Inc. (NASDAQ:PTGX)

Market Cap: $287M

Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform which is utilized to discover and develop novel peptide-based drugs. Its primary focus is on developing potential oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by marketed injectable antibody drugs.

 

Zogenix, Inc. (NASDAQ:ZGNX)

Market Cap: $957M

zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders.


So why are investors so excited?

This pharmaceutical technology doesn’t only target the GI system, but can be helpful for a variety other maladies as well, such as epilepsy or cancer. According to a market research report, the global Central Nervous System (CNS) therapeutic market was worth $77.2 billion in 2016 and is anticipated to grow at a 5.9% compound annual growth rate through 2025. Grandview Research found that the mental health segment “dominated” the market in 2016 and should continue to do so, while cancer is expected to become the fastest growing segment.

With rapid advancement and drug development coming in the year ahead, Vitality Biopharma (VBIO:OTCQB) is a stock to watch in the immediate future.

———————–

Sources:

https://www.reportlinker.com/p04688591/Global-Market-Study-on-Crohn-s-Disease-Anti-inflammatory-Drugs-Segment-Anticipated-to-be-the-Most-Lucrative-Segment-Through.html


Get the Investor Report on This Company




DISCLAIMER:
This is a paid advertisement and all individuals should verify all claims and perform their own due diligence on VBIO (and / or any other mentioned companies and / or securities), and read this disclaimer in its entirety. FinancialPress.com profiles are not a solicitation or recommendation to buy, sell or hold securities. FinancialPress.com is a paid advertiser and is not offering securities for sale. Neither FinancialPress.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by FinancialPress.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. FinancialPress.com does not recommend that the securities profiled should be purchased, sold or held and is not liable for any investment decisions by its readers or subscribers. Information presented by FinancialPress.com may contain “forward-looking statements ” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance, are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements may be identified through the use of words such as “expects, ” “will, ” “anticipates,” “estimates,” “believes,” “may,” or by statements indicating that certain actions “may,” “could,” or “might” occur. 

THIS SITE IS PROVIDED BY FINANCIALPRESS.COM ON AN “AS IS” AND “AS AVAILABLE” BASIS. FINANCIALPRESS.COM MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, AS TO THE OPERATION OF THIS SITE OR THE INFORMATION, CONTENT, MATERIALS, OR PRODUCTS INCLUDED ON THIS SITE. YOU EXPRESSLY AGREE THAT YOUR USE OF THIS SITE IS AT YOUR SOLE RISK. TO THE FULL EXTENT PERMISSIBLE BY APPLICABLE LAW, FINANCIALPRESS.COM DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. FINANCIALPRESS.COM DOES NOT WARRANT THAT THIS SITE, IT’S SERVERS, OR E-MAIL SENT FROM FINANCIALPRESS.COM ARE FREE OF VIRUSES OR OTHER HARMFUL COMPONENTS. FINANCIALPRESS.COM, ITS MEMBERS, MANAGERS, OWNERS, AGENTS, AND EMPLOYEES WILL NOT BE LIABLE FOR ANY DAMAGES OF ANY KIND ARISING FROM THE USE OF THIS SITE, INCLUDING, BUT NOT LIMITED TO DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, AND CONSEQUENTIAL DAMAGES. CERTAIN STATE LAWS DO NOT ALLOW LIMITATIONS ON IMPLIED WARRANTIES OR THE EXCLUSION OR LIMITATION OF CERTAIN DAMAGES. IF THESE LAWS APPLY TO YOU, SOME OR ALL OF THE ABOVE DISCLAIMERS, EXCLUSIONS, OR LIMITATIONS MAY NOT APPLY TO YOU, AND YOU MIGHT HAVE ADDITIONAL RIGHTS. 


By using FinancialPress.com, you agree, without limitation or qualification, to be bound by, and to comply with, these Terms of Use and any other posted guidelines or rules applicable. The website contains links to other related World Wide Web Internet sites and resources. FinancialPress.com is not responsible for the availability of these outside resources, or their contents, nor does FinancialPress.com endorse nor is FinancialPress.com responsible for any of the contents, advertising, products or other materials on such sites. Under no circumstances shall FinancialPress.com be held responsible or liable, directly or indirectly, for any loss or damages caused or alleged to have been caused by use of or reliance on any content, goods or services available on such sites. Any concerns regarding any external link should be directed to its respective site administrator or webmaster. You agree to indemnify and hold FinancialPress.com, its officers, directors, owners, agents and employees, harmless from any claim or demand, including reasonable attorneys fees, made by any third party due to or arising out of your use of the website, the violation of these Terms of Use by you, or the infringement by you, or other user of the website using your computer, of any intellectual property or other right of any person or entity. We reserve the right, at our own expense, to assume the exclusive defense and control of any matter otherwise subject to indemnification. 

FinancialPress.com is owned and operated by Stock Social Inc. We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (the “Information”) about publicly traded companies (the “Profiled Issuers”). We publish the Information on our website, financialpress.com and in newsletters, text message alerts, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer and / or third party paying us. Our publication of the Information is known as a “Campaign”. This information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. Typically, the trading volume and price of a Profiled Issuer’s securities increases after the information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer trading losses if they purchase the securities of a Profiled Issuer late in a Campaign. We are paid to advertise the Profiled Issuers Vitality Biopharma, Inc. FinancialPress.com has been hired by Vitality Biopharma, Inc. (VBIO) and also an unrelated third party, Full Service Media / Pyronix Media Inc., for a period beginning on October 11, 2017 and is scheduled to end on December 7, 2017 to publicly disseminate information about Vitality Biopharma, Inc. (VBIO) via website, native ads, social media and email. We have been issued 32,468 restricted shares for a hold period of six months from Vitality Biopharma Inc., and a total of one hundred and fifty thousand US dollars from Full Service Media / Pyronix Media Inc. We will update any changes to our compensation.  


Vitality Biopharma Inc. (VBIO) is a penny stock, and therefore these securities are subject to wide fluctuations in trading price and volume. During the Campaign the trading volume and price of the securities of each Profile Issuer will likely increase significantly because of the media exposure. When the Campaign ends, the volume and price of the Profiled Issuer will likely decrease dramatically. As a result, investors who purchase during the Campaign and hold shares of the Profiled Issuer when the Campaign ends will probably lose most, if not all, of their investment. The Information we publish in the Campaign is only a snapshot that provides only positive information about the Profiled Issuers. The Information consists of only positive content. We do not and will not publish any negative information about the Profiled Issuers; accordingly, investors should consider the Information to be one-sided and not balanced, complete, accurate, truthful and / or reliable. We do not verify or confirm any portion of the Information. We do not conduct any due diligence, nor do we research any aspect of the Information including the completeness, accuracy, truthfulness and / or reliability of the Information. We do not review the Profiled Issuers’ financial condition, operations, business model, management or risks involved in the Profiled Issuer’s business or an investment in a Profiled Issuer’s securities. All information in our Campaign is publicly available information from 3rd party sources and / or the Profiled Issuers and/or the 3rd parties that hire us. We may also obtain the Information from publicly available sources such as the OTC Markets, TSX, CSE, Google, NASDAQ, NYSE, Yahoo, Bing, the Securities and Exchange Commission’s Edgar or Sedar database or other available public sources. We select the stocks we profile and / or pick as we are compensated to advertise them. If an investor relies solely on the Information in making an investment decision it is highly probable that the investor will lose most, if not all, of his or her investment. Investors should not rely on the Information to make an investment decision. The source of our compensation varies depending upon the particular circumstances of the Campaign. In certain cases, we are compensated by the Profiled Issuers, third party shareholders, and / or other parties related to the Profiled Issuers such as officers and/or directors who will derive a financial or other benefit from an increase in the trading price and/or volume of a Profiled Issuer’s securities. 

We make no warranty and / or representation about the Information, including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the Information is at your own risk. The Information is provided as is without limitation. We are not, and do not act in the capacity of any of the following; as such, you should not construe our activities as involving any of the following: 

• An independent adviser or consultant; 

• A fortune teller; 

• An investment adviser or an entity engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal and / or state level; 

• A broker-dealer or an individual acting in the capacity of a registered representative or broker; 

• A stock picker; 

• A securities trading expert; 

• A securities researcher or analyst; 

• A financial planner or one who engages in financial planning; 

• A provider of stock recommendations; 

• A provider of advice about buy, sell or hold recommendations as to specific securities; or 

• An agent offering or securities for sale or soliciting their purchase. 


There are numerous risks associated with each Profiled Issuer and investors should undertake a full review of each Profiled Issuer with the assistance of their financial, legal, and tax advisers prior to purchasing the securities of any Profiled Issuer. We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest. Third parties that have hired us and own shares will sell these shares while we tell investors to purchase, and this selling of the Profiled Issuer’s securities will likely cause investors to suffer losses. Our publication of the Information involves actual and material conflicts of interest including but not limited to the fact that we receive monetary compensation in exchange for publishing the (favorable) Information about the Profiled Issuers; and we do not publish any negative information, whatsoever, about the Profiled Issuers; in addition to the fact that while we do not own the Profiled Issuer’s securities, the third parties that hired us do, and intend to sell all of these securities during the Campaign while we publish favorable information that instructs investors to purchase, and this selling of the Profiled Issuer’s securities will likely cause investors to suffer losses. We are not responsible or liable for any person’s use of the Information or any success or failure that is directly or indirectly related to such person’s use of the Information because we have specifically stated that the information is not reliable and should not be relied upon for any purpose. We are not responsible for omissions and / or errors in the Information and we are not responsible for actions taken by any person who relies upon the Information. We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and / or investment adviser(s). An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products and / or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. An investor’s review should include, but not be limited to a review of available public sources and information received directly from the Profiled Issuers or from websites such as Google, Yahoo, Bing, OTC Markets, TSX, CASE, NASDAQ, NYSE, Edgar, Sedar or other available public sources. We are providing you with this disclaimer because we are publishing advertisements about penny stocks. Because we are paid to disseminate the Information to the public about securities, we are required by the securities laws including Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose my compensation as well as other important information, This information includes that we may hold, as well as purchase and sell, the securities of a Profiled Issuer before, during and after we publish favorable Information about the Profiled Issuer. We may urge investors to purchase the securities of a Profiled Issuer while we sell my own shares. The anti-fraud provisions of federal and state securities laws require us to inform you that we may engage in buying and selling of Profiled Issuer’s securities before, during and after the Campaigns. Any investment in the Profiled Issuers involves a high degree of risk and uncertainty.

The securities may be subject to extreme volume and price volatility, especially during the Campaigns. Favorable past performance of a Profiled Issuer does not guarantee future results. If you purchase the securities of the Profiled Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Profiled Issuers include, but are not limited to the risks stated below. We do not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. We conduct no due diligence or investigation whatsoever of the Information or the Profiled Issuers and we do not receive any verification from the Profiled Issuer regarding the Information we disseminate. If we publish any percentage gain of a Profiled Issuer from the previous day close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment. The Information may contain statements asserting that a Profiled Issuer’s stock price has increased over a certain period of time which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon the (favorable) Information in your analysis of the present or future potential of a Profiled Issuer or its securities. The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Profiled Issuer’s future stock price or future financial performance. You may encounter difficulties determining what, if any, portions of the Information are material or non-material, making it all the more imperative that you conduct your own independent investigation of the Profiled Issuer and its securities with the assistance of your legal, tax and financial advisor. When 3rd parties that hire us acquire, purchase and / or sell the securities of the Profiled Issuers, it may (a) cause significant volatility in the Profiled Issuer’s securities; (b) cause temporary but unrealistic increases in volume and price of the Profiled Issuer’s securities; (c) if selling, cause the Profiled Issuer’s stock price to decline dramatically; and (d) permit themselves to make substantial profits while investors who purchase during the Campaign experience significant losses. The securities of the Profiled Issuers are high risk, unstable, unpredictable and illiquid which may make it difficult for investors to sell their securities of the Profiled Issuers. We may hire third party service providers and stock promoters to electronically disseminate live news regarding the Profiled Issuers, yet we have no control over the content of and do not verify the information that the Profiled Issuers and/or third party service providers publish. These third party service providers are likely compensated for providing positive information about the Issuer and may fail to disclose their compensation to you. If a Profiled Issuer is an SEC reporting company, it could be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports), or if it is an OTC Markets Pink Sheet quoted company, it may be delinquent in its Pink Sheet reporting obligations, which may result in OTC Markets posting a negative legend pertaining to the Profiled Issuer at www.otcmarkets.com, as follows: (i) “Limited Information” for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) “No Information,” which characterizes companies that are unable or unwilling to provide any disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) “Caveat Emptor,” signifying buyers should be aware that there is a public interest concern associated with a company’s illegal spam campaign, questionable stock promotion, known investigation of a company’s fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions. If the Information states that a Profiled Issuer’s securities are consistent with the future economic trends or even if your independent research indicates that, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and/or government may react in unforeseen ways and be affected by behavioral biases that we are unable to predict; (c) human and social factors may outweigh future economic trends that we state may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of new circumstances and situations in which uncertainty becomes reality rather than predicted economic outcome; or (f) if the trend predicted involves a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies. The Information is presented only as a brief snapshot of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities. You should consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.otcmarkets.com or other electronic media, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the OTCMarkets.com; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.org. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative legends and designations at otcmarkets.com. FinancialPress.com, reserves the right, at its sole discretion, to change, modify, add and/ or remove all or part of this Disclaimer and / or Terms of Use at any time


To contact The Financial Press, please contact us at: newsroom@financialpress.com

 

Continue Reading

Uncategorized

Style Tips From Top Designer of United States

Published

on

By

It is important to be chic. I love the 2000s because everyone started to love haute couture. I always say: To be well dressed you must be well naked. I am never satisfied with myself and that is what keeps me going – I have no post-satisfaction. The difference between style and fashion is quality.

Art is Concern for Learning and Living

Possibly we do not have one theme for each season, but just try to make beautiful clothes all year round. We have got to change our ethics and our financial system and our whole way of understanding the world. It has to be a world in which people live rather than die; a sustainable world. It could be great.

Even Michelangelo got paid for doing the Sistine Chapel. To those artists who say they’re doing it for the love of art, I say: Get real.

Also Read: Nicole Kidman on the Critic’s Choice Red Carpet Event of 2017

Fashion fosters cliches of beauty, walking in the streets of style.

It is difficult to talk about fashion in the abstract, without a human body before my eyes, without drawings, without a choice of fabric – without a practical or visual reality. Brides today are increasingly sensitive to the tastes, feelings and finances of their attendants. Fashion is about dressing according to what’s fashionable. Style is more about being yourself. If you wear clothes that don’t suit you, you’re a fashion victim. You have to wear clothes that make you look better. Art is about learning and about living with people. It’s alive.

But ultimately, the main message is to forget about rules – after all, one look at Stone’s beauty history proves she’s tried everything from peacock blues to punchy corals and made it work for the red carpet.

Vanity is the Healthiest Thing in Life

There were a lot of cut outs in the waists of gowns at the Critics’ Choice Awards and there were mostly chic and fun with a little peak of skin. This is not a little peak.

Walking on the fashion show of Elementos

They will all come together to decide the winner of the prize, which was won last year by British menswear designer Grace Wales Bonner. The successful candidate will be given a €300,000 grant and year-long business mentorship, helping them to develop every area of their brand.

Coverage: 50 Ways to Wear a Hat

We like the idea of a long top over pants – it’s nervy – but the combo of no straps, very long layers of ruffling and her cleavage looking smashed the latest records.

This is reflected in the basic idea to Kate Ballis’ photo series Beaches Above. By shooting the world from a bird’s eye view world.

Success isn’t about the end result, it’s about what you learn along the way. Fashion fosters cliches of beauty, but I want to tear them apart. I wanted to dress the woman who lives and works, not the woman in a painting. For me, the summer will be pure gray – mother-of-pearl gray, very pale gray. To me, this is the big statement for summer. Then we have light blue, light turquoise, lots of pink. Women are more sure of themselves today. They don’t have to emulate the way men dress.

1. There is always the new project, the new opportunity.

A stylish purse for the La La Land.

Her pictures show the seaside of Brighton, Sandringham, St. Kilda and Albert Park in Melbourne. The photographs were taken from a Robinson helicopter with the door off: “I hang directly out of the helicopter which is very scary but I’m getting used to it,” she says confidently. “The photos were taken on a 40 degree day in Melbourne, which means that it’s actually a nice temperature in the helicopter.”

2. The idea of a beach holiday is a bit nostalgic in itself. To me, this is the big statement for summer.

Pulling off an awesome dress at outskirts.

While from a ground level perspective the world often looks pretty messy, Kate’s photos capture a certain order that lies within these landscapes. Her images can even be compared to paintings depicting life many years prior. Kate has an explanation for why that might persist.

It is about striving to do as well as possible, for yourself, not for outside approval; and not worrying excessively about mistakes or set-backs.

I am like a freight train. Working on the details, twisting them and playing on them over the years, but always staying on the same track.

Valentino Garavani

People who exhibit unhealthy perfectionism are fearful of failure, fearful of criticism, hate making mistakes, stew over past errors, and worry excessively about disappointing others. You can counter this by trying to develop a healthy perfectionist approach.

Forget Your Fears and Worries

Success isn’t about the end result, it’s about what you learn along the way. Fashion fosters cliches of beauty, but I want to tear them apart. I wanted to dress the woman who lives and works, not the woman in a painting. For me, the summer will be pure gray – mother-of-pearl gray, very pale gray.

  • I’m used to always deciding everything myself.
  • It’s a blessing, but also a terrible defect sensational.
  • Style is much more interesting than fashion, really.
  • Garbriela Peters partnered with YouTube.

“Forget what people tell you is the right thing and go with what you love,” Goodwin proclaimed. “Make-up is supposed to be fun and if you are so attached to doing what’s right it loses its joy. Have fun with it!”

Continue Reading

Uncategorized

Easy Boho Style: Without Looking Like a Coachella Victim

Published

on

By

It is important to be chic. I love the 2000s because everyone started to love haute couture. I always say: To be well dressed you must be well naked. I am never satisfied with myself and that is what keeps me going – I have no post-satisfaction. The difference between style and fashion is quality.

Art is Concern for Learning and Living

Possibly we do not have one theme for each season, but just try to make beautiful clothes all year round. We have got to change our ethics and our financial system and our whole way of understanding the world. It has to be a world in which people live rather than die; a sustainable world. It could be great.

Even Michelangelo got paid for doing the Sistine Chapel. To those artists who say they’re doing it for the love of art, I say: Get real.

Also Read: Nicole Kidman on the Critic’s Choice Red Carpet Event of 2017

Fashion fosters cliches of beauty, walking in the streets of style.

It is difficult to talk about fashion in the abstract, without a human body before my eyes, without drawings, without a choice of fabric – without a practical or visual reality. Brides today are increasingly sensitive to the tastes, feelings and finances of their attendants. Fashion is about dressing according to what’s fashionable. Style is more about being yourself. If you wear clothes that don’t suit you, you’re a fashion victim. You have to wear clothes that make you look better. Art is about learning and about living with people. It’s alive.

But ultimately, the main message is to forget about rules – after all, one look at Stone’s beauty history proves she’s tried everything from peacock blues to punchy corals and made it work for the red carpet.

Vanity is the Healthiest Thing in Life

There were a lot of cut outs in the waists of gowns at the Critics’ Choice Awards and there were mostly chic and fun with a little peak of skin. This is not a little peak.

Walking on the fashion show of Elementos

They will all come together to decide the winner of the prize, which was won last year by British menswear designer Grace Wales Bonner. The successful candidate will be given a €300,000 grant and year-long business mentorship, helping them to develop every area of their brand.

Coverage: 50 Ways to Wear a Hat

We like the idea of a long top over pants – it’s nervy – but the combo of no straps, very long layers of ruffling and her cleavage looking smashed the latest records.

This is reflected in the basic idea to Kate Ballis’ photo series Beaches Above. By shooting the world from a bird’s eye view world.

Success isn’t about the end result, it’s about what you learn along the way. Fashion fosters cliches of beauty, but I want to tear them apart. I wanted to dress the woman who lives and works, not the woman in a painting. For me, the summer will be pure gray – mother-of-pearl gray, very pale gray. To me, this is the big statement for summer. Then we have light blue, light turquoise, lots of pink. Women are more sure of themselves today. They don’t have to emulate the way men dress.

1. There is always the new project, the new opportunity.

A stylish purse for the La La Land.

Her pictures show the seaside of Brighton, Sandringham, St. Kilda and Albert Park in Melbourne. The photographs were taken from a Robinson helicopter with the door off: “I hang directly out of the helicopter which is very scary but I’m getting used to it,” she says confidently. “The photos were taken on a 40 degree day in Melbourne, which means that it’s actually a nice temperature in the helicopter.”

2. The idea of a beach holiday is a bit nostalgic in itself. To me, this is the big statement for summer.

Pulling off an awesome dress at outskirts.

While from a ground level perspective the world often looks pretty messy, Kate’s photos capture a certain order that lies within these landscapes. Her images can even be compared to paintings depicting life many years prior. Kate has an explanation for why that might persist.

It is about striving to do as well as possible, for yourself, not for outside approval; and not worrying excessively about mistakes or set-backs.

I am like a freight train. Working on the details, twisting them and playing on them over the years, but always staying on the same track.

Valentino Garavani

People who exhibit unhealthy perfectionism are fearful of failure, fearful of criticism, hate making mistakes, stew over past errors, and worry excessively about disappointing others. You can counter this by trying to develop a healthy perfectionist approach.

Forget Your Fears and Worries

Success isn’t about the end result, it’s about what you learn along the way. Fashion fosters cliches of beauty, but I want to tear them apart. I wanted to dress the woman who lives and works, not the woman in a painting. For me, the summer will be pure gray – mother-of-pearl gray, very pale gray.

  • I’m used to always deciding everything myself.
  • It’s a blessing, but also a terrible defect sensational.
  • Style is much more interesting than fashion, really.
  • Garbriela Peters partnered with YouTube.

“Forget what people tell you is the right thing and go with what you love,” Goodwin proclaimed. “Make-up is supposed to be fun and if you are so attached to doing what’s right it loses its joy. Have fun with it!”

Continue Reading

Most Popular